Sanochemia Pharmazeutika AG
http://www.sanochemia.at/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sanochemia Pharmazeutika AG
ARS Gets Early FDA Approval For Needle-Free Epinephrine
ARS will compete directly with EpiPen and other injectable products with inhaled neffy as the first needle-free epinephrine therapy for severe allergy attacks. EU approval is thought imminent.
Deal Watch: Revance To Go Private In Crown Laboratories Buyout
Plus deals involving AstraZeneca/Conduit, Recursion/Exscientia, G1/Pharmacosmos, Sanofi/Vir, Passage Bio/GEMMA and Lupin/Evofem. Also including deals in brief.
ARS Gets Early FDA Approval For Needle-Free Epinephrine
ARS will compete directly with EpiPen and other injectable products with inhaled neffy as the first needle-free epinephrine therapy for severe allergy attacks. EU approval is thought imminent.
Lykos’s Knockback Could Be An Opportunity For Rivals
The group intends to appeal the US FDA’s rejection of its MDMA-based PTSD therapy, midomafetamine, but other psychedelics could advance in the meantime.
Company Information
- Industry
- Biotechnology
- Contract Research, Toxicology Testing-CRO
- Distributors
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
-
Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
-
- Alvetra et al Werfft GmbH
- SANOCHEMIA Diagnostics Deutschland GmbH
- SANOCHEMIA Diagnostics International Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice